Free Trial
NASDAQ:ORIC

Oric Pharmaceuticals Q2 2025 Earnings Report

Oric Pharmaceuticals logo
$10.60 +0.22 (+2.12%)
Closing price 04:00 PM Eastern
Extended Trading
$10.59 -0.01 (-0.09%)
As of 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oric Pharmaceuticals EPS Results

Actual EPS
-$0.47
Consensus EPS
-$0.46
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Oric Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oric Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Oric Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Oric Pharmaceuticals Earnings Headlines

Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
See More Oric Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oric Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oric Pharmaceuticals and other key companies, straight to your email.

About Oric Pharmaceuticals

Oric Pharmaceuticals (NASDAQ:ORIC) is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents. In addition, ORIC-944, a potent inhibitor of discoidin domain receptors 1 and 2 (DDR1/2), is in late preclinical development for modulation of fibrotic tumor stroma and metastatic disease control. Oric applies translational biology and biomarker-driven strategies to guide patient selection and optimize therapeutic indices across its programs.

Founded in 2016 by a team of oncology R&D veterans, Oric Pharmaceuticals completed its initial public offering on the Nasdaq Global Market in March 2021 under the ticker symbol ORIC. The company has established collaborative relationships with leading academic institutions and clinical research organizations across North America and Europe to support its global clinical development plans. Its senior management team is led by President and Chief Executive Officer Johanna Mercier, Ph.D., who brings extensive experience in small molecule drug discovery and development from prior roles at major pharmaceutical companies.

Oric leverages a proprietary target discovery platform that integrates genomic, proteomic and functional screening data to uncover resistance pathways and potential combination strategies. By incorporating biomarker analyses early in development, the company aims to accelerate timelines and deliver therapies with differentiated mechanisms of action. Multiple programs are advancing through IND-enabling studies, with key clinical milestones anticipated over the coming 12 months.

View Oric Pharmaceuticals Profile

More Earnings Resources from MarketBeat